Anticancer drug resistance in primary human brain tumors

Brain Research Reviews

Volumn 35, Issue 2, 2001, Pages 161-204

  Bredel, Markus ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Anaplastic oligodendroglioma; Apoptosis; Dihydrofolate reductase (DHFR); Glutathione (GSH); Glutathione S transferase (GST); High grade glioma; Human brain tumors; Individual drug resistance (IDR); Lung resistance related protein (LRP); Metallothionein (MT); Multidrug resistance (MDR); Multidrug resistance associated protein (MRP); Multiple drug resistance 1 (Mdr1) gene; O6 methylguanine DNA methyltransferase (MGMT); P glycoprotein (Pgp); Protein kinase C (PKC); Temozolomide; Thymidylate synthase (TS); Topoisomerase II (Topo II)

Indexed keywords

1 (2 CHLOROETHYL) 3 (2,6 DIOXO 3 PIPERIDYL) 1 NITROSOUREA; 3' DEAMINO 3' MORPHOLINOOXAUNOMYCIN; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DIHYDROFOLATE REDUCTASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ELMUSTINE; ETOPOSIDE; FOTEMUSTINE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; IFOSFAMIDE; IRINOTECAN; LOMUSTINE; LUNG RESISTANCE PROTEIN; METALLOTHIONEIN; METHOTREXATE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN; NIMUSTINE; PROTEIN KINASE C; SEMUSTINE; TEMOZOLOMIDE; TENIPOSIDE; THYMIDYLATE SYNTHASE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

APOPTOSIS; BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CROSS RESISTANCE; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; DRUG UPTAKE; HUMAN; MEMBRANE TRANSPORT; MULTIDRUG RESISTANCE; NONHUMAN; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR RESISTANCE; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN; BRAIN NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENZYMES; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035016885     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(01)00045-5     Document Type: Review

References (452)

1. Possible involvement of multidrug-resistance-associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells
2. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1
3. Expression of multidrug resistance protein gene in patients with glioma after chemotherapy
4. Indentification of dihydrofolate reductase in human cental-nervous-system tumours
5. Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, and cis-diamminedichloroplatinum (II) in human glial-derived cell lines
6. 6-alkylguanine-DNA-alkyltransferase activity potentiates cytotoxicity and induction of SCEs in human glioma cells resistant to 1,3-bis(2-chloroethyl)-1-nitrosouea
7. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and cdk-2, as well as induction of cdk inhibitor p21 in p53-mutated human carcinoma cells
8. Effect of UCN-01, a selective inhibitor of protein kinase C on the cell-cycle distribution of human epidermoid carcinoma, A431 cells
9. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase-p gene variants
10. Buthionine sulfoximine induction of gamma-l-glutamyl-l-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicitiy in human glioma cells
11. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells
12. Prognostic significance of glutathione S-transferase p expression and subcellular localization in human gliomas
13. Decreased DNA interstrand cross-linking and cytotoxicity induced in human brain tumor cells by 1,3-bis(2-chloroethyl)-1-nitrosourea after in vitro reaction with glutathione
14. Formation and repair of 1,3-bis-(2-chloroethyl)-1-nitrosourea and cisplatin induced total genomic DNA interstrand crosslinks inhuman glioma cells
15. DNA interstrand crosslinking and strand break repair human glioma cell lines of varying [1,3-bis(2-chloroethyl)-1-nitrosourea] resistance
16. Glutathione content and glutathione S-transferase expression in 1,3-bis(2-chloroehtyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines
17. Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells
18. Characterization of the human ABC superfamily: Isolation and mapping of 21 new genes using the expressed sequence tags database
19. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells
20. Modulation of metallothionein-III mRNA content and growth rate of rat C6-glial cells by transfection with human 5-HT1D receptor genes
21. The role of protein kinase C and phosphatidylinositol cycle in multidrug resistance in human ovarian cancer cells
22. Technetium-MIBI as a glioma imaging agent for the assessment of multidrug resistance
23. The role of jun, fos and the AP-1 complex in cell proliferation and transformation
24. Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis
25. Chemotherapy of malignant brain tumors-scientific basis for combination chemotherapy
26. Protein kinase C isoform alpha overexpression in C6 glioma cells and its role in cell proliferation
27. Protein kinase C and growth regulation of malignant gliomas
28. Purine and pyrimidine metabolism in human gliomas: Relation to chromosomal aberrations
29. Experimental chemotherapy of neuroblastoma. II. Increased thymidylate synthetase activity in a 5-fluorodeoxyuridine-resistant variant of mouse neuroblastoma
30. Altered thymidine kinase or thymidylate synthetase activities in 5-fluorodeoxyuridine resistant variants of mouse neuroblastoma
31. A comparison of thymidylate synthetase activities from 5-fluorodeoxyuridine sensitive and resistant variants of mouse neuroblastoma
32. Cellular sensitization to cis-diamminedichloroplatinum (II) by novel analogues of protein kinase C activator lyngbyatoxin A
33. Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum (II) by bryostatin 1
34. Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum (II)
35. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas
36. Alterations in DNA methylation: A fundamental aspect of neoplasia
37. The multidrug resistance gene MDR1 is expressed in human glial tumors
38. New mechanisms of hormone secretion: MDR-like gene products as extrusion pumps for hormones?
39. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine
40. Expression pattern of alpha-protein kinase C in human astrocytomas indicates a role in malignant progression
41. Thymidylate synthase overproduction and gene amplification in flurodeoxyuridine-resistant human cells
42. Role of protein kinase C in glial proliferation
43. A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma
44. Selective regulation of expression of protein kinase C (PKC) isoenzymes in multi-drug resistant MCF-7 cells
45. Genetic heterogneity of the human glutathione S-transferases: A complex of gene families
46. 6-methylguanine-DNA methyltransferase to resistance to 1,3-(chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines
47. 6-alkylguanine DNA adducts in glioma-derived human cells resistant to the cytotoxic and cytogenetic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea
48. 6-(2-chloroethyl)guanine mediates the biological effects of chloroethylnitrosoureas
49. Investiation of resistance to DNA cross-linking agents in 9L cell lines with different sensitivities to chloroethylnitrosoureas
50. Potentiation of 1,3-bis(chloroethyl)-1-nitrosourea (BCNU)-induced cytotoxicity in 9L cells by pretreatment with 6-thioguanine
51. Reduced level of DNA cross-links and sister chromatid exchanges in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant rat brain tumor cells
52. Differences in DNA alkylation products formed in sensitive and resistant human glioma cells treated with N-(2-chloroethyl)-N-nitrosourea
53. DocMOAT (MRP2), other MRP homologues, and LRP play a role in MDR?
54. Immunohistochemical expression of P-glycoprotein and glutathione S-transferases in cerebral gliomas and response to chemotherapy
55. Use of verapamil to enhance the antiproliferative activity of BCNU in human glioma cells: An in vitro and in vivo study
56. Temozolomide in patients with high grade gliomas
57. Detection of DNA damage in transcriptionally active genes by RT-PCR and assessment of repair of cisplatin-induced damage in the glutathione S-transferase-pi gene in human glioblastoma cells
58. The p21-Ras signal transduction pathway and growth regulation in high-grade gliomas
59. The role of protein kinase C (PKC) in the evolution and proliferation of malignant gliomas, and the application of PKC inhibition as a novel approach to anti-glioma therapy
60. Inhibition of ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth
61. Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion
62. Suppression of cross-link formation in chloroethylnitrosourea-treated DNA by an activity in extracts of human leukemic lymphblasts
63. Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents
64. Transport proteins in drug resistance: Detection and prognostic significance in acute myeloid leukemia
65. Pharmacology of drug transporter in multidrug resistant tumor cells
66. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMRP, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats
67. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor
68. Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias
69. A mechanism of cellular resistance to drugs that interfere with microtubule assembly
70. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
71. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissue
72. Quinazoline antifolates as inhibitors of growth, dihydrofolate reductase, and thymidylate synthetase of mouse neuroblastoma cells in culture
73. Correlation of protein kinase C translocation, P-glycoprotein phosphorylation and reduced drug accumulation in multidrug resistant human KB cells
74. Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells
75. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma
76. The suppression of drug-induced apoptosis by activation of v-abl protein tyrosine kinase
77. Activation of MDR 1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists
78. DNA topoisomerases: Essential enzymes and lethal targets
79. Internal dublication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells
80. 6 glioma cells
81. Direction of p21-Ras generated signals towards cell growth or apoptosis is determined by protein kinase C and bcl-2
82. Excision repair cross-complementing rodent deficiency gene 2 expression and chloroethylnitrosourea resistance in human glioma cell lines
83. Ependymomas in children express the multidrug resistance gene: Immunohistochemical and molecular biologic study
84. Multidrug resistance gene expression in childhood medulloblastoma: Correlation with clinical outcome and DNA ploidy in 29 patients
85. Antifolates
86. Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex
87. 6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary
88. 6-methylguanine-DNA methyltransferase gene MGMT in human normal and tumor tissues
89. Characterization and differential distribution of the three major protein kinase C isozymes of the central nervous system in normal and Alzheimer's disease brains
90. Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy
91. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
92. Pharmacological characterization of the multidrug resistant MRP-transfected human tumor cells
93. Role of glutathione in cellular resistance to alkylating agents
94. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
95. Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C
96. Protein kinase C and growth regulation in malignant gliomas
97. Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines
98. Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro
99. Thymidylate synthase: A target enzyme in cancer chemotherapy
100. Subcellular distribution of the α and β topoisomerase II-DNA complexes stabilized by VM-26
101. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins
102. Defective repair of alkylated DNA by human tumor and SV40-transformed human cell strains
103. Human tumor cell strains defective in the repair of alkylation damage
104. Resistance to cisplatin and analogues; mechanism and potential clinical implications
105. Programmed cell death (apoptosis) and cancer chemotherapy
106. Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and resistant rat glioblastoma cells
107. Signal transduction events for the suppression of apoptosis
108. Metallothionein and anticancer agents: The role of metallothionein in cancer chemotherapy
109. Dihydrofolate reductase in primary brain tumors, cell cultures of central nervous system origin, and normal brain during fetal and neonatal growth
110. The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells of glioblastoma multiforme
111. Topoisomerase II is a structural component of mitotic chromosome scaffolds
112. Localization of topoiomerase II in mitotic chromosomes
113. Metallothioneins and other zinc-binding proteins in brain
114. Do metallothioneins affect the response to treatment in testis cancer?
115. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression
116. The biochemistry of P-glycoprotein-mediated multidrug resistance
117. 6-methylguanine DNA methyltransferase (MGMT) in drug resistance and strategies for its inhibtion
118. DNA cross-linking and monoadduct repair in nitrosourea-treated human tumor cells
119. 6-methylguanine-DNA methyltransferase by promotor hyermethylation is a common event in primary human neoplasia
120. Suppression of apoptosis by v-Abl protein tyrosine kinase is associated with nuclear translocation and activation of protein kinase C in an interleukin-3-dependent haematopoietic cell line
121. Glutathione and related enzymes in rat brain tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea and nitrogen mustard
122. Multiple pathways to apoptosis
123. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents
124. MDR1 gene expression in primary brain tumors (MBT)
125. Drug resistance in brain tumors
126. Role of nuclear protein kinase C in the mitogenic response to platelet-derived growth factor
127. Phorbol esters induce multidrug resistance in human breast cancer cells
128. Immunohistochemical detection of the multidrug resistance-associated protein (MRP) in human multidrug-resistant tumor cells by monoclonal antibodies
129. Tissue distribution of the multidrug resistance protein
130. 6-methylguanine DNA methyltransferase gene MGMT in MER+ and MER- human tumor cells
131. Cyclophosphamide resistance in medulloblastoma
132. Temozolomide and treatment of malignant glioma
133. 6-alkylguanine-DNA-alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma
134. Topoisomerase poisons: Harnessing the dark side of enzyme mechanism
135. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines
136. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
137. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer
138. Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine
139. Detection multidrug resistance gene product (P-glycoprotein) expression in ependymomas
140. Multidrug resistance
141. P-glycoprotein - A mediator of multidrug resistance in tumour cells
142. Improved treatment of a brain-tumor model: Part 2. Sequential therapy with BCNU and 5-fluorouracil
143. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53
144. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate
145. Expression of a multidrug-resistance gene in human cancer
146. Multidrug resistance in human cancer
147. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis
148. Posttranscriptional regulation of MRP/GS-X pump and gamma-glutamylcysteine synthetase expression by 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea and by cycloheximide in human glioma cells
149. Transient induction of the MRP/GS-X pump and gamma-glutamylcysteine synthetase by 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea in human glioma cells
150. Elevated expression of DNA polymerase beta gene in glioma cell lines with acquired resistance to 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea
151. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs
152. Glutathione S-transferases and cytochrome P450 detoxifying enzyme distribution in human cerebral glioma
153. P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy
154. Isolation and expression of a complementary DNA that confers multidrug resistance
155. Surgery, radiation, and chemotherapy in the treatment of malignant brain tumors
156. p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors
157. Accumulation of class I mutant p53 and apoptosis induced by carboplatin in a human glioma cell line
158. Identification of placental form of glutathione S-transferase in ACNU-resistant murine glioma cell lines
159. Localization of the placental form of glutathione S-transferase messenger ribonucleic acid in human glioma cell lines
160. Expression of the placental form of glutathione S-transferase in pediatric gliomas
161. Immunoblot analysis of the placental form of glutathione S-transferase in protein extracted from paraffin-embedded human glioma tissue
162. Immunohistochemical demonstration of the placental form of glutathione S-transferase, a detoxifying enzyme in human gliomas
163. 6-methylguanine-DNA methyltransferase gene
164. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance
165. 6-methylguanine-DNA methyltransferase in six human medulloblastoma cell lines
166. Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle
167. Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells
168. Immunohistochemical study of topoisomerase IIa expression in primary ductal carcinoma of the breast
169. P-glycoprotein expression in brain tumors
170. Expression of topoisomerase II, bcl-2, and p53 in three human brain tumor cell lines and their possible relationship to intrinsic resistance to etoposide
171. Apoptosis and chemotherapy resistance
172. ABC transporters: From microorganisms to man
173. Microsomal metabolism of nitrosoureas
174. Detection of the Mr 190,000 multidrug resistance protein, MRP, with monoclonal antibodies
175. Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer
176. Identification of a multidrug resistance associated antigen (P-glycoprotein) in human normal tissues
177. Immunohistochemical analysis of metabollothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and surival
178. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas
179. The distribution of immunoreactive topoisomerase II protein in human tissues and neoplasms
180. Immunohistochemical staining for DNA topoisomerase II in frozen and formalin-fixed paraffin-embedded human tissues
181. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: Correlation with MIB1 expression and patient survival
182. Coming undone: How to untangle a chromosome
183. O-6-methylguanine-DNA methyltransferase protein levels in pediatric brain tumors
184. Specific induction of ACNU-resistance in V79 Chinese hamster cells and C6 rat glioma cells
185. 6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications
186. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines
187. P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines
188. Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors
189. Effect of glutathione-modulating compounds on hydrogen peroxide-induced cytotoxicity in human glioblastoma and glioma cell lines
190. Apoptosis of human glioma cells in response to calphostin C, a specific protein kinase C inhibitor
191. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss
192. Chromosomal localization of human glutathione transferase genes of classes alpha, mu, and pi
193. Immunohistochemical study of Ki-67 and DNA topooisomerase II in human endometrium
194. Association of p53 gene muation with decreased chemosensitivity in human malignant gliomas
195. Inhibitory effects of tamoxifen and tumor necrosis factor alpha on human glioblastoma cells
196. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors
197. Major vault protein LRP-related multidrug resistance
198. Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs
199. Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma
200. Characterization and chemosensitivity of two cell lines derived from human glioblastomas
201. Acquired methotrexate resistance in lymphoblasts resulting from altered kinetic properties of dihydrofolate reductase
202. Expression of topoisomerase IIa is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer
203. Significance of metallothionein overexpression in human tumours
204. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein
205. Thymidylate synthase gene amplification in fluorodeoxyuridine-resistant mouse cell lines
206. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines
207. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer
208. A surface glycoprotein in modulating drug permeability in Chinese hamster ovary cell mutants
209. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines
210. Topoisomerase II levels and drug sensitivity in adult myelogenous leukemia
211. Isolation and characterization of a novel ribonucleoprotein particle: Large structures contain a single species of small RNA
212. Co-amplification of erbB2, topoisomerase IIa and retinoid acid receptor genes in breast cancer and allelic loss at topoisomerase I on chromosome 20
213. Translational inhibition of messenger RNA of the human pi class glutathione S-transferase by antisense oligodeoxyribonucleotides
214. Overexpression of the metallothionein confers resistance to anticancer drugs
215. Hepatic canalicular membrane 5: Expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver
216. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
217. The sequence of a cDNA encoding the major vault protein from Rattus norvegicus
218. Induction of metallothionein in a human astrocytoma cell line by interleukin-1 and heavy metals
219. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3)
220. Intracellular targeting of protein kinase C isoenzymes, functional implications
221. Expression of glutathione S-transferases α and π in gastric cancer: A correlation with cisplatin resistance
222. Overexpression of multidrug resistance protein gene in human cancer cell lines selected for drug resistance to epipodophyllotoxins
223. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis
224. Mdm2 gene mediates the expression of Mdr1 gene and P-glycoprotein in a human glioblastoma cell line
225. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis
226. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines
227. Prognostic value of the immunoexpression of chemoresistance-related proteins in cerebral glioblastomas: An analysis of 168 cases
228. 6-methylguanine-DNA methyltransferase (MGMT) expression in Mer- human tumor cell lines
229. Qunatitative analysis of glutathione in human brain tumors
230. Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate
231. Induction of resistance to etoposide and adriamycin in a human glioma cell line treated with antisense oligonucleotide complementary to the messenger ribonucleic acid of deoxyribonucleic acid topoisomerase II alpha
232. Intraarterial O-6-benzylguanine enables the specific therapy of notrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea
233. Differentiation of neuroblastoma enhances Bcl-2 expression and induces alterations in apoptosis and drug resistance
234. Role of protein kinase activity in apoptosis
235. Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter
236. Elevated level of nuclear protein kinase C in multidrug-resistant MCF-7 human breast carcinoma cells
237. 6-methylguanine-DNA-methyltransferase and N3-methyladenine-DNA-glycosylase in human cells exposed to DNA-damaging agents
238. Multidrug resistance in human cancer
239. 4 and structurally related conjugates
240. Uptake and distribution of 3H-methotrexate by the murine ependymoblastoma
241. BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors
242. Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance
243. Multidrug resistance in glioblastoma. Chemosensitivity resting and immunohistochemical demonstration of p-glycoprotein
244. Gluthatione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: Intrinsic differences and cell cycle effects
245. Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines
246. Structure of the human MDR3 and physical mapping of the human MDR locus
247. Non-P-glycoprotein drug export mechanisms of multidrug resistance
248. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia
249. The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia
250. Overexpression of the major vault protein transporter lung-resistance protein predicts treatment outcome in acute myeloid leukemia
251. Structure of the human allelic glutathione S-transferase-pi gene variant, hGSTP1*C, cloned from a glioblastoma multiforme cell line
252. Genomic cloning of hGSTP1*C, an allelic Pi class glutathione S-transferase gene variant and functional characterization of its retinoic acid response elements
253. Biology of the multidrug resistance-associated protein
254. p53 status and the efficacy of cancer chemotherapy in vitro
255. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
256. Human DNA topoisomerase II-alpha: A new marker of proliferation in invasive breast cancer
257. Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine
258. Metallothionein overexpression in human brain tumors
259. Multidrug resistance in leukemias and its reversal
260. Nomenclature for human glutathione transferases
261. Gluthione transferases. Stucture and catalytic activity
262. 6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo
263. Mechanisms of multidrug resistance in HL-60 cells: Detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the reduced sequence of P-glycoprotein
264. Human DNA topoisomerase II-alpha: Immunohistochemical staining for enzyme protein in tumors of ovarian origin
265. Differential involvement of protein kinase C isozymes in Alzheimer's disease
266. Topoisomerase II deletion as well as amplification associated with erbB2 amplification in breast cancer
267. Amplification and expression of a multidrug resistance gene in human glioma cell lines
268. Expression of P-glycoprotein in human glioma cell lines and surgical glioma specimens
269. Determinants of drug response in camptothecin-11-resistant glioma cell lines
270. Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line
271. Quantitative analysis of glutathione and glutathione S-transferase in human brain tumors, C6 rat glioma cells and drug resistant C6 cells
272. Ex vivo activity of methorexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells
273. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis
274. Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status
275. Phospholipase C-gamma is a substrate for the PDGF and EGF receptor protein-tyrosine kinases in vivo and in vitro
276. A family of human cdc2-related protein kinases
277. 6-methylguanine-DNA methyltransferase activity in cerebral gliomas. A guidance for nitrosourea treatment?
278. 6-methylguanine in ACNU-resistant brain tumors
279. 6-methylguanine-DNA mehyltransferase activity on chloroethylnitrosourea chemotherapy in brain tumors
280. 6-alkylguanine-DNA alkyltransferase activity in human brain tumors
281. 6-methylguanine-DNA methyltransferase mRNA in human brain tumors
282. Human brain tumor O[6]-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy
283. Protein kinase C isoforms in human glioblastoma cells
284. Reversal of vinblastine resistance by a new staurosporine derivate, NA-382 in P388/ADR cells
285. Prognostic significance of the expression of metallothionein, glutathione S-transferase pi and P-glycoprotein in curatively resected gastric cancer
286. Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells
287. Cowan K. Glutathione S-transferases and drug resistance
288. A study of the expression of four chemoresistance-related genes in human primary and metastatic brain tumors
289. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport
290. Phorbol ester stimulates the proliferation of astrocytes in primary culture
291. Multidrug-resistance gene (MDR1) expression in human brain tumors
292. 6-methylguanine-deoxyribonucleic acid methyltransferase messenger ribonucleic acid for therapy of malignant gliomas
293. 6-methylguanine-DNA methyltransferase and chloroethylnitrosourea resistance of human brain tumors
294. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases
295. Investigation of chemoresistance-related genes mRNA expression for selecting anticancer agents in successful adjuvant chemotherapy for a case of recurrent glioblastoma
296. Inhibition of human glioma cell proliferation and glutathione S-transferase by ascorbyl esters and interferon
297. Inhibition of cell proliferation and glutathione S-transferase by ascorbyl esters and interferon in mouse glioma
298. Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma
299. Immunohistochemical study of placental form of glutathione S-transferase in human brain tumors and fetal brains
300. Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11
301. Qualitative and quantitative histochemical evaluation of the dehydrogenase actitvity in human glioblastoma cells treated with beta-interferon
302. p27 modulates cell cycle progression and chemosensitivity in human malignant glioma
303. Differential sensitivity of double minute chromosomes to hydroxyurea treatment in cultured methotrexate-resistant mouse cells
304. P53 gene mutations in lymphoid diseases an their possible relevance to drug resistance
305. Vertebrate cdc2 kinase its regulation by phosphorylation and its mitotic targets
306. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C
307. The molecular heterogenity of protein kinase C and its implications for cellular regulation
308. The role of protein kinase C in cell surface signal transduction and tumor promotion
309. Antitopoisomerase drug action and resistance
310. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II
311. Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line
312. Association between high levels of expression of the multidrug
313. 6-methylguanine-DNA mehyltransferase in tumors and cells of the oligodendrocyte lineage
314. Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy
315. Selective cytoplasmic and membrane changes induced by cisplatinum
316. Glutathione and related enzymes in multidrug resistance
317. 6-methylguanine-DNA methyltransferase in malignant human glioma cell lines
318. Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma
319. Multiple-drug resistance in human cancer
320. 6-alkylguanine-DNA alkyltransferase regulation and importance in response to alkylating carcinogenic and therapeutic agents
321. Prognostic importance of thymidylate synthase expression in early breast cancer
322. Glutathione S-transferases, gene structure, regulations, biological function
323. 6-methylguanine-DNA methyltransferase gene (MGMT) mRNA levels in MER+ and MER- human tumor cell lines containing the MGMT gene by the polymerase chain reaction technique
324. Homozygous deletions of the CDKN2C/p18INK4C gene on the short arm of chromosome 1 in anaplastic oligodendroglioma
325. Patterns of growth factor, growth factor receptor and second messenger expression in pediatric brain tumors
326. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor
327. Response of malignant glioma cell lines to activation and inhibition of protein kinase C-mediated pathways
328. Changes in protein kinase C isoenzyme expression associated with apoptosis in U937 myelomonocytic cells
329. Human multidrug resistant KB cells overexpress protein kinase C: Involvement in drug resistance
330. Protein kinase C in adriamycin action and resistance in mouse sarcoma 180 cells
331. Doxorubicin-induced alterations of c-myc and c-jun gene expression in rat glioblastoma cells: Role of c-jun in drug resistance and cell death
332. 6-methylguanine-DNA methyltransferase activity in breast and brain tumors
333. Study of the antioxidant enzymes in human brain tumors
334. Evaluation of apoptosis in four human tumour cell lines with differing sensitivities to cisplatin
335. Physical mapping, amplification, and overexpression of the mouse mdr gene family in multidrug-resistant cells
336. Bcl-2: Prevention of apoptosis as a mechanism of drug resistance
337. Platinum analogs in cancer
338. Wechsler W: Immunohistochemical determination of protein kinase C expression and proliferative activity in human brain tumors
339. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines
340. Purification of P-glycoprotein form plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability
341. 6-methylguanine-DNA methyltransferase
342. The mechanism of DNA topoisomerases
343. DNA transport by a type II DNA topoisomerases: Evidence in favor of a two-gate mechanism
344. Unlocking vaults: Organelles in search of a function
345. Stem cell studies human malignant brain tumors. Part 1: Development of the stem assay and its potential
346. Brain-tumor therapy: Quantitative analysis using a model system
347. Pores for thought: Nuclear pore complex proteins
348. Overexpressed WAF1/Cip1 renders gioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin
349. Protein kinase C phosphorylates topoisomerase II. Topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells
350. Glutiathione and cellular response of ACNU-resistant rat glioma sublines to drugs and radiation
351. Mechanisms of interaction of thymidylate synthase with 5-fluorodeoxyuridylate folates in pyrimidine nucleotide biosynthesis
352. Mechanisms of interaction of thymidylate synthase with 5-fluorodeoxyuridylate
353. DNA cross-linking response of human malignant glioma cell strains to chloroethylnitrosoureas, cisplatin and diaziquone
354. Fos-associated cellular p39 is related to nuclear transcription factor AP-1
355. Induction of metallothionein in astrocytes by cytokines and heavy metals
356. 2 and the alpha subtype of protein kinase C
357. Expression of the multidrug-resistance P-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors
358. Molecular basis of cisplatin resistance in human carcinomas: Model systems and patients
359. The drug resistance-related protein LRP is the human major vault protein
360. Overexpression of a 110 kD vesicular protein in non-P-glycoprotein mediated multidrug-resistance
361. Transporter molecules in multdrug resistance
362. Distribution of the mouse md1a P-glycoprotein gene leads to deficiency in the blood-brain barrier and to increased sensitivity to drugs
363. The blood-brain barrier: Morphology, molecules, neurothelin
364. Spontaneous multidrug transport in human glioma cells is regulated by transforming growth factor type beta
365. 6-alkylguanine-DNA alkyltransferase and sensivity to procarbazine in human brain-tumor xenografts
366. The multidrug-resistance P-glycoprotein (Pgp, MDR1) is an early marker of blood-brain barrier development in the microvessels of the developing human brain
367. 6-methylguanine in DNA to inactivation by alkylating agents including chloroethylnitrosoureas
368. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells
369. Induction of apoptosis in glioblastoma cells by inhibition of protein kinase C and its association with the rapid accumulation of p53 and induction of the insulin-like growth factor-1-binding protein-3
370. Type-specific expression of protein kinase C isozymes in human brain tumours
371. Presence and possible significance of immunocytochemically demonstrable metallothionein overexpression in primary invasive ductal carcinoma of the breast
372. 6-methylguanine-DNA methyltransferase activity in adult gliomas: Relation to patient and tumor characteristics
373. 6-methylguanine-DNA methyltransferase activity in brain tumors and adjacent normal brain
374. The prognostic role of p53, metallothionein, P-glycoprotein and MIB-1 in muscle invasive urothelial transitional cell carcinoma
375. Mechanisms of resistance to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) in sensitive and resistant human glioma cells
376. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas
377. Topoisomerase IIa co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: Relationship to m-AMSA and mitoxantrone sensitivity
378. Denitrosation of 1,3-bis(2-chloroethyl) 1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells
379. Drug resistance in multiple myeloma
380. In vivo kinetics of thymidylate synthase inhibition in 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas
381. Doxorubicin-induced cell death in highly invasive human gliomas
382. The human glutathione S-transferases: Comparison of isoenzyme expression in normal and astrocytoma brain
383. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2
384. BCL-2 family protein expression in initial and recurrent glioblastomas: Modulation by radiochemotherapy
385. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16
386. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells
387. s sensitizes MCF-7 cells to chemotherapy-induced apoptosis
388. EGF induces biphasic S6 kinase activation: Late phase is protein kinase C-dependent and contributes to mitogenicity
389. DNA topoisomerase IIa is the major chromosome protein recognized by the mitotic phosphorprotein antibody MPM-2
390. 6-alkylguanine-DNA-alkyltransferase and sensitivity to BCNU of human xenografts
391. In vivo etoposide-resistant C6 glioma cell line: Significance of altered DNA topoisomerase II activity in multi-drug resistance
392. ++-phospholipid-dependent protein kinase (protein kinase C)
393. Ultrastructural localization of P-glycoprotein on capillary endothelial cells in human gliomas
394. Significance of topoisomerase II in clinical breast cancer
395. Immunohistochemical staining of DNA topoisomerase II α in human gliomas
396. Analysis of the Chinese hamster P-glycoprotein/multidrug resistance gene pgp1 reveals that the AP-1 site is essential for full promoter activity
397. Glutathione-associated enzymes in anticancer drug resistance
398. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
399. Apoptosis in the pathogenesis and treatment of disease
400. Expression of glutathione transferase π as a predictor for treatment results at different stages of acute nonlymphoblastic leukemia
401. Development of multidrug resistance in a primitive neuroectodermal tumor cell line
402. Multidrug resistance gene expression in pediatric primitve neuroectodermal tumors of the central nervous system
403. Immunohistochemical demonstration of protein kinase C isozymes in human brain tumors
404. Comparison of in vitro activity of epipodophyllotoxins with other chemotherapeutic agents in human medulloblastomas
405. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors
406. Chemosensitivity of human malignant glioma: Modulation by p53 gene transfer
407. Immunocytochemical detection of DNA topoisomerase type II in primary breast carcinomas: Correlation with clinicopathological features
408. Dihydrofolate reductase activity in primary brain tumors in children
409. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein
410. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone
411. Multidrug resistance
412. Cortisol is transported by the multidrug resistance gene product P-glycoprotein
413. cDNA cloning and distribution of the major vault protein a gene (mvpA) in Dictyostelium discoideum
414. Overexpression of bax in human glioma cell lines
415. Multridrug resistance and its reversal
416. Expression of lung resistance protein (LRP) in non-small cell lung carcinomas of smokers and non-smokers and its predictive value for doxorubicin resistance
417. Associated expression of protein kinase C with resistance to doxorubicin in human lung cancer
418. Gene transfer of human TNF alpha into glioblastoma cells permits modulation of Mdr1 expression and potentiation of chemosensitivity
419. DNA topoisomerases
420. Distinct patterns of phorbol ester-induced down-regulation of protein kinase C activity in adriamycin-selected multidrug resistant and parental murine fibrosarcoma cells
421. Indentification of a new glutathione S-transferase in human liver
422. Increased levels of thymidylate synthase in cells exposed to 5-fluorouracil
423. Structure and function of type II DNA topoisomerases
424. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
425. Glutathione S-transferases: Role in alkylating agent resistance and possible target for modulation chemotherapy: A review
426. 6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU
427. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene
428. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation
429. Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses
430. Hyericin-induced apoptosis of human malignant glioma cells is ligh-dependent, independent of bcl-2 expression, and does not require wild-type p53
431. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier
432. Brain tumor chemotherapy with intrathecal methotrexate
433. Proliferation and cell-cycle dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells
434. Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170 kDA and 180 kDA froms of topoisomerase II
435. Glutathione S-transferase-π: Its minimal promoter and downstream cis-acting element
436. Drug resistance and apoptosis in ENU-induced rat brain tumors treated with anti-cancer drugs
437. 6-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis
438. Application of SPET using technetium-99m sestamibi in brain tumors and comparison with expression of the MDR-1 gene: Is it possible to predict the response to chemotherapy in patients with gliomas by means of 99m Tc-sestamibi SPET?
439. Proliferation of human and mouse astrocytes in vitro: Signaling through the protein kinase C pathway
440. Overcoming of ACNU resistance in an ACNU-resistant subline of rat C6 glioma in vivo through enhanced effect of ACNU by calmodulin inhibitor
441. Isolation and preliminary characterization of ACNU-resistant sublines of rat brain tumors in vivo
442. Possibility of overcoming ACNU resistance in ACNU-resistant sublines of rat brain tumors in vitro by a calmodulin inhibitor
443. Mechanism and overcoming of resistance in ACNU-resistant sublines of rat brain tumors
444. Studies on the mechanism of ACNU resistance in sublines of rat C6 glioma and 9L gliosarcoma in vitro
445. Expression of multidrug resistance protein-related genes in lung cancer: Correlation with drug response
446. Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein
447. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump
448. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug-resistant lung cancer cell lines
449. High levels of constitutive WAF1/Cip 1 protein are associated with chemoresistance in acute myelogenous leukemia
450. Growth inhibition and apoptosis in human neuroblastoma SK-N-SH cells induced by hypericin, a potent inhibitor of protein kinase C
451. 6-methylguanine-DNA methyltransferase-mediated nimustine resistance in recurrent malignant gliomas by streptozotocin - A preliminary report
452. Differential effects of phorbol ester on apoptosis in HL-60 promyelocytic leukemia cells